Key Takeaways
- Vir Biotechnology plans to offer $200 million in common stock, with a potential additional $30 million from underwriters.
- The offering will be managed by Goldman Sachs, Leerink Partners, Evercore ISI, and Barclays.
- The shares will be sold under an existing shelf registration statement with the SEC, allowing a streamlined sales process.
Company Announcement
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company, has announced plans for an underwritten public offering of $200 million worth of its common stock. There is also an option for underwriters to purchase an additional $30 million in shares, providing the company with financial flexibility.
The public offering is contingent on market conditions and the successful completion of regulatory requirements. All shares offered in this transaction will be issued by Vir Biotechnology. Prominent financial firms, including Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, and Barclays, will serve as the book-running managers, ensuring that the offering is managed efficiently.
This offering will employ an automatically effective shelf registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023. This registration facilitates a smoother and quicker process for the company to raise capital by allowing the sale of shares without undergoing lengthy approvals each time.
A preliminary prospectus supplement will be submitted to the SEC, detailing the terms of the offering. Interested investors can request this document from the underwriters directly or access it through the SEC’s website.
It is important to note that this announcement does not constitute an offer to sell or solicit an offer to buy shares in any jurisdiction where such transactions would be illegal without prior registration.
To clarify, Vir Biotechnology is focused on harnessing the immune system to fight serious infectious diseases and cancer, with a range of clinical and preclinical development programs. Its project portfolio includes advanced therapies for chronic hepatitis delta and multiple solid tumor targets. This latest funding initiative is part of the company’s strategy to continue expanding its innovative treatment offerings.
Careful attention must be given to the forward-looking statements included in the release, as these reflect expectations that could be influenced by numerous variables, including market conditions and regulatory compliance. Vir Biotechnology cautions investors against placing undue reliance on these statements as actual outcomes could significantly differ.
For further information, investors are encouraged to direct their queries to the company’s communication director or investor relations head via email.
The content above is a summary. For more details, see the source article.